iX Biopharma Ltd. (42C.SI)

0.0420 +0.0010 (+2.44%) At close: 03:14PM SGT

iX Biopharma Ltd.

No. 14-01 Great World City East Lobby
1 Kim Seng Promenade
Singapore 237994
Singapore
65 6235 2270
https://www.ixbiopharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Prof. Chin Beng Lim	Chief Pharmacist	N/A	N/A	N/A
Mr. Yip Hang Lee	Executive Chairman & CEO	N/A	N/A	1954
Mr. Sien Lup Chew	Chief Financial Officer	N/A	N/A	1963
Dr. Janakan Krishnarajah	COO & Chief Medical Officer	N/A	N/A	N/A
Dr. Iain Bruce Cook	Chief Scientist	N/A	N/A	1960
Ms. Eva Tan	Chief Commercial Officer	N/A	N/A	N/A
Mr. Kuan Loong Lai	Secretary	N/A	N/A	N/A
Ms. Soo Fern Lee ACIS	Secretary	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.

Description

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Pharmaceutical and Nutraceutical segments. It offers Wafermine, a sublingual ketamine wafer, which has completed phase-2 clinical trial for the treatment of acute moderate to severe pain and complex regional pain syndrome; Xativa, a sublingual cannabidiol wafer, as well as Hypera, a tetrahydrocannabinol sublingual wafer for the treatment of anxiety, chronic pain, inflammation, and insomnia; and Wafesil and Silcap for the treatment of male erectile dysfunction. The company also provides LumeniX, a sublingual glutathione wafer for skin brightening and immunity; Radiance for reducing wrinkles, smoothening the skin, and promoting a youthful complexion; Regenerate that supports cellular health and aids energy production; WafeRest for the alleviating jetlag and promotion of sleep; and SL-NAD+ supplement products. In addition, it is involved in the development BnoX, a sublingual buprenorphine wafer that is in a phase-1 clinical trial for the management of moderate to severe pain; Dexmedetomidine, which has completed phase-1 clinical trial for agitation in dementia patients; Dronabinol for chemotherapy-induced nausea, vomiting, and anorexia associated with weight loss in patients with HIV/AIDS; IXB-214, which is in phase-1 clinical trial for the treatment of complex regional pain syndrome; IXB-314 that is in phase-1 clinical trial for the treatment-resistant depression; IXB-321, a sublingual vaccine wafer; iXB-322 for respiratory viral prophylaxis; and iXB-320 for anorexia in HIV/chemoinduced nausea and vomiting. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.

Corporate governance

iX Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.